FABRX partners with SRC to distribute their 3D pharmaceutical printers across Canada and North America

Spectra Research Corporation Partners with FABRX to Distribute Innovative Pharmaceutical 3D Printers and Services Across Canada

Spectra Research Corporation (SRC) is pleased to announce a new partnership with FABRX, a leading provider of pharmaceutical 3D printers, software, and pharma-ink development services. This collaboration will bring FABRX’s cutting-edge technology for personalized medicine and small batch manufacturing to the Canadian market, revolutionizing drug development and clinical trials.

FABRX is renowned for its M3DIMAKER pharmaceutical 3D printers, the world’s first GMP-ready pharmaceutical 3D printer series. These printers come equipped with exchangeable printheads and optional built-in quality control capabilities, enabling the fully personalized manufacture of precision medicine for both human and veterinary applications. The M3DIMAKER series supports extemporaneous and compounding preparation regulations using standard pharmaceutical excipients, making it a versatile tool for modern pharmaceutical practices.

A look at FABRX product portfolio:

M3DIMAKER 1 Pharmaceutical 3D Printer product imageM3DIMAKER 1 M3DIMAKER 2

Key Features of M3DIMAKER Pharmaceutical 3D Printers:

  • GMP-Ready: Ensures compliance with Good Manufacturing Practices, crucial for pharmaceutical production.
  • In-Built Quality Control: Optional features for enhanced quality assurance.
  • Exchangeable Printheads: Easy cleaning and flexibility for diverse printing needs and personalized medicine manufacturing.
  • Comprehensive Software: User-friendly software packages for printer control, quality assurance, user tracking and data storage plus extra packages for patient feedback collection, facilitating streamlined workflows and data management.

In addition to their advanced printers, FABRX offers pharma-ink development services. Their team of world-leading scientists assists in designing, developing, and testing 3D printable pharma-inks tailored to specific active ingredients. They also support the manufacture of small batches of novel medication, ideal for clinical trials.

“We are thrilled to partner with FABRX and bring their innovative pharmaceutical 3D printing technology to Canada,” said Serge Dandache, General Manager at Spectra Research Corporation. “This collaboration aligns with our mission to provide cutting-edge solutions to the scientific community and enhance the capabilities of drug development and personalized medicine.”

For more information about the M3DIMAKER 3D printers and to explore how this technology can benefit your pharmaceutical research and development, please visit SRC’s website.

SRC logo

About Spectra Research Corporation (SRC): Spectra Research Corporation (SRC) is a leading distributor of scientific instrumentation and solutions across Canada. SRC partners with world-renowned manufacturers to provide advanced technology and support for various industries, including pharmaceuticals, materials science, and nanotechnology.

About FABRX: FABRX is a pioneering company in the field of pharmaceutical 3D printing, offering a range of products and services designed to facilitate personalized medicine and small batch manufacturing. With a focus on innovation and quality, FABRX continues to lead the way in developing new solutions for the pharmaceutical industry.